Showing 551-560 of 1846 results for "".
Conversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiUpdates on AD Therapeutics
https://practicaldermatology.com/topics/atopic-dermatitis/updates-on-ad-therapeutics/19760/It's a "super-exciting" time in the world of atopic dermatitis because of a number of new developments happening very rapidly, shares Peter Lio, MD. Recent approvals and additional indications for treatments like dupilumab and crisaborole in pediatric populations have been welcome additions. And theNew eRelevance Services, Cosmetic Bootcamp Updates, Leo & AID Partnership
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-new-erelevance-services-cosmetic-bootcamp-updates-leo-aid-partnership/18291/eRelevance has launched a suite of 4 services intended to support aesthetic practices in optimizing their marketing strategies to capture, convert, and retain patients. CEO Bob Fabbio discusses. Aesthetic education takes center stage at Cosmetic Boot Camp in Aspen. The meeting is open only to boardDermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for DuobValeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicDermWireTV: Ped Derm Salaries; Skin Cancer Symposium Kicks Off; Pandemic Self Care Stats
https://practicaldermatology.com/topics/practice-management/dermwiretv-ped-derm-salaries-skin-cancer-symposium-kicks-off-pandemic-self-care-stats/19910/According to the Society for Pediatric Dermatology’s 2020 Pediatric Dermatology Physician Compensation Report, salaries have increased 37% since 2014. Pediatric dermatologist Mercedes Gonzalez, MD comments. The inaugural Skin Cancer Symposium is underway and the Symposium for Inflammatory Disease kiAesthetic Advances: New Technology
https://practicaldermatology.com/conferences/cosmetic-surgery-forum-2022/aesthetic-advances-new-technology/20160/Suneel Chilukuri, MD discusses the benefits of some of the new devices he’s using to improve outcomes for his aesthetic patients. He says BTL’s Emface offers him the ability to tighten and tone the facial muscles and lift neck muscles. He describes the benefits of the Sylfirm X RF microneedling systDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improves